The alpha-5 helix of Bax is sensitive to ubiquitin-dependent degradation

Biochemical and Biophysical Research Communications

Volumn 371, Issue 1, 2008, Pages 10-15

  Yu, Ming ^a   Liu, Feng Ting ^a   Newland, Adrian C ^a   Jia, Li ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Apoptosis; Bax; Degradation

Indexed keywords

MUTANT PROTEIN; PROTEASOME; PROTEIN BAX; PROTEIN BAX ALPHA5; UBIQUITIN;

ALPHA HELIX; AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CANCER CELL; GENE DELETION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN STABILITY;

AMINO ACID SEQUENCE; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SEQUENCE DELETION; UBIQUITIN;

EID: 42749083788     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.03.122     Document Type: Article

References (22)

1. Matsumoto H., Wada T., Fukunaga K., Yoshihiro S., Matsuyama H., and Naito K. Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. Jpn. J. Clin. Oncol. 34 (2004) 124-130
2. Chang H.J., Jung K.H., Kim D.Y., Jeong S.Y., Choi H.S., Kim Y.H., Sohn D.K., Yoo B.C., Lim S.B., Kim D.H., Ahn J.B., Kim I.J., Kim J.M., Yoon W.H., and Park J.G. Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum. Pathol. 36 (2005) 364-371
3. Nehls O., Okech T., Hsieh C.J., Sarbia M., Borchard F., Gruenagel H.H., Gaco V., Porschen R., Gregor M., and Klump B. Low BAX protein expression correlates with disease recurrence in preoperatively irradiated rectal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 61 (2005) 85-91
4. Khor L.Y., Moughan J., Al-Saleem T., Hammond E.H., Venkatesan V., Rosenthal S.A., Ritter M.A., Sandler H.M., Hanks G.E., Shipley W.U., and Pollack A. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin. Cancer Res. 13 (2007) 3585-3590
5. Kang S.Y., Han J.H., Lee K.J., Choi J.H., Park J.I., Kim H.I., Lee H.W., Jang J.H., Park J.S., Kim H.C., Kang S., Oh Y.T., Chun M., Kim J.H., Sheen S.S., and Lim H.Y. Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin. Cancer Res. 13 (2007) 4146-4153
6. Chang Y.C., Lee Y.S., Tejima T., Tanaka K., Omura S., Heintz N.H., Mitsui Y., and Magae J. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 9 (1998) 79-84
7. Li B., and Dou Q.P. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc. Natl. Acad. Sci. USA 97 (2000) 3850-3855
8. Liu F.T., Agrawal S.G., Gribben J.G., Ye H., Du M.Q., Newland A.C., and Jia L. Bortezomib blocks Bax degradation in malignant B-cells during treatment with TRAIL. Blood 111 (2008) 2797-2805
9. Agrawal S.G., Liu F.T., Wiseman C., Shirali S., Liu H., Lillington D., Du M.Q., Syndercombe-Court D., Newland A.C., Gribben J.G., and Jia L. Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. Blood 111 (2008) 2790-2796
10. Suzuki M., Youle R.J., and Tjandra N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 103 (2000) 645-654
11. Cartron P.F., Gallenne T., Bougras G., Gautier F., Manero F., Vusio P., Meflah K., Vallette F.M., and Juin P. The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol. Cell 16 (2004) 807-818
12. Parikh N., Koshy C., Dhayabaran V., Perumalsamy L.R., Sowdhamini R., and Sarin A. The N-terminus and alpha-5, alpha-6 helices of the pro-apoptotic protein Bax, modulate functional interactions with the anti-apoptotic protein Bcl-xL. BMC Cell Biol. 8 (2007) 16
13. George N.M., Evans J.J., and Luo X. A three-helix homo-oligomerization domain containing BH3 and BH1 is responsible for the apoptotic activity of Bax. Genes Dev. 21 (2007) 1937-1948
14. Nouraini S., Six E., Matsuyama S., Krajewski S., and Reed J.C. The putative pore-forming domain of Bax regulates mitochondrial localization and interaction with Bcl-X(L). Mol. Cell Biol. 20 (2000) 1604-1615
15. Nguyen M., Millar D.G., Yong V.W., Korsmeyer S.J., and Shore G.C. Targeting of Bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. J. Biol. Chem. 268 (1993) 25265-25268
16. Schinzel A., Kaufmann T., Schuler M., Martinalbo J., Grubb D., and Borner C. Conformational control of Bax localization and apoptotic activity by Pro168. J. Cell Biol. 164 (2004) 1021-1032
17. Er E., Lalier L., Cartron P.F., Oliver L., and Vallette F.M. Control of Bax homodimerization by its carboxyl terminus. J. Biol. Chem. 282 (2007) 24938-24947
18. Breitschopf K., Zeiher A.M., and Dimmeler S. Ubiquitin-mediated degradation of the proapoptotic active form of Bid. A functional consequence on apoptosis induction. J. Biol. Chem. 275 (2000) 21648-21652
19. Musti A.M., Treier M., and Bohmann D. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 275 (1997) 400-402
20. H. Wolfgang, D.H. Wolf. Molecular Biology Intelligence Unite, 12, Proteasomes: The World of Regulatory Proteolysis. Eurekah.com/Landes Bioscience, Texas, USA, 2000.
21. Garcia-Saez A.J., Mingarro I., Perez-Paya E., and Salgado J. Membrane-insertion fragments of Bcl-xL, Bax, and Bid. Biochemistry 43 (2004) 10930-10943
22. Cao X., Deng X., and May W.S. Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax. Blood 102 (2003) 2605-2614